ClinicalTrials.gg
CompletedNCT01082380Updated Feb 29, 2012Results posted

Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers

A Phase 1 interventional study of PF-02341066 in Healthy Volunteer, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-29.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066 in humans.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • radiolabeled
  • healthy volunteers
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead and clinical laboratory tests).
  • (BMI) of 17.5 to 30.5 kg/m\^2; and a total body weight >50 kg (110 lbs).

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • A positive urine drug screen.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    1

    Drug: PF-02341066

Interventions

  • oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of \[14C\]PF 02341066

    Also known as: crizotinib

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours (hrs), 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  3. Area Under the Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast)

    Area under the concentration time-curve from zero to the last measured plasma concentration (AUClast).

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  4. Area Under the Plasma Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  5. Plasma Decay Half Life (t1/2)

    Plasma Decay half-life is the time measured for the concentration to decrease by one half.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  6. Apparent Oral Clearance (CL/F) of Plasma PF-02341066

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  7. Apparent Volume of Distribution (V/F) in Plasma

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  8. Renal Clearance (CLr) of PF-02341066

    CLr is the volume of plasma from which a substance is completely removed by the kidney in a given amount of time.

    Time frame: Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose

  9. Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to Infinite Time (Ae)

    Ae = concentration of unchanged drug excreted in the urine multiplied by volume of unchanged drug excreted in urine.

    Time frame: Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose

  10. Total Amount of Unchanged Drug Excreted in the Urine Expressed as Percent of Dose From Time Zero to Infinite Time [Ae(%)]

    Time frame: Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose

  11. Maximum Observed Concentration in Plasma Radioactivity (Cmax)

    Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  12. Time to Reach Maximum Observed Plasma Radioactivity Concentration (Tmax)

    Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  13. Area Under the Curve From Time Zero to Last Quantifiable Plasma Radioactivity Concentration (AUClast)

    Area under the concentration time-curve from zero to the last measured plasma concentration. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  14. Area Under the Plasma Radioactivity Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

    Area under the concentration curve from time zero to extrapolated infinite time \[AUC (0 - ∞)\] in plasma. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  15. Decay Half Life (t1/2) of Radioactivity in Plasma

    Plasma decay half-life is the time measured for the plasma radioactivity concentration to decrease by one half. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  16. Apparent Oral Clearance (CL/F) of Plasma Radioactivity

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  17. Apparent Volume of Distribution (V/F) in Plasma Radioactivity

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  18. Maximum Observed Concentration of Radioactivity in Whole Blood (Cmax)

    Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  19. Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in Whole Blood

    Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  20. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Radioactivity in Whole Blood

    Area under the concentration time-curve from zero to the last measured concentration (AUClast) in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  21. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Radioactivity in Whole Blood

    Area under the concentration curve from time zero to extrapolated infinite time \[AUC (0 - ∞)\] in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  22. Decay Half-life (t1/2) of Radioactivity in Whole Blood

    Decay half life (t1/2) is the time measured for the concentration to decrease by one half in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  23. Apparent Oral Clearance of Radioactivity From Whole Blood (CL/F)

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  24. Apparent Volume of Distribution of Radioactivity in Whole Blood (V/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  25. Total [14C] Data in Urine

    Cumulative amount excreted in urine at specified intervals after administration of a single 250-mg (100 μCi) oral dose of \[14C\]PF-02341066.

    Time frame: Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose

  26. Total [14C] Data in Feces

    Cumulative amount excreted in feces at specified intervals after administration of a single 250-mg (100 μCi) oral dose of \[14C\]PF-02341066.

    Time frame: From Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose

  27. Overall Cumulative Percent Recovery of Radioactivity

    Overall cumulative percent of radioactive dose recovered in urine, feces and toilet tissue at specified intervals after administration of a single 250-mg (100 μCi) oral dose of \[14C\]PF-02341066.

    Time frame: Pre-dose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose for urine and Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose for feces

  28. Identification and Profiling of Metabolites of [14C]PF-02341066 in Plasma

    Identification was done by Radio-High Performance liquid chromatography (HPLC) chromatogram. Relative abundance (profiling) of metabolites in chromatogram were determined by dividing sum of radioactive content of fractions contributing to particular peak by sum of radioactive content of all fractions constructing the radio chromatogram. Metabolites accounting for an average of greater than or equal to (\>=) 10% of total recoverable radioactivity in plasma were summarized. Radioactivity corresponds to 100 μCi \[14C\] PF-02341066.

    Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose

  29. Identification and Profiling of Metabolites of [14C]PF-02341066 in Feces

    In feces, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of \>=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi \[14C\] PF-02341066.

    Time frame: From Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose

  30. Identification and Profiling of Metabolites of [14C]PF-02341066 in Urine

    In urine, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of \>=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi \[14C\] PF-02341066.

    Time frame: Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose

07

Results

Posted Oct 26, 2011

Participant flow

Participant flow — Overall Study
MilestonePF-02341066 250 mg
Started6
Completed6
Not completed0

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours (hrs), 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLPF-02341066 250 mg
Maximum Observed Plasma Concentration (Cmax)109.400 ± 54.153
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrPF-02341066 250 mg
Time to Reach Maximum Observed Plasma Concentration (Tmax)2.99 (1.98 to 6.00)
PrimaryArea Under the Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast)

Area under the concentration time-curve from zero to the last measured plasma concentration (AUClast).

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast)
ng*hr/mLPF-02341066 250 mg
Area Under the Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast)2686.0 ± 1119.6
PrimaryArea Under the Plasma Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
ng*hr/mLPF-02341066 250 mg
Area Under the Plasma Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]2777.0 ± 1114.9
PrimaryPlasma Decay Half Life (t1/2)

Plasma Decay half-life is the time measured for the concentration to decrease by one half.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Mean · hr
Plasma Decay Half Life (t1/2)
hrPF-02341066 250 mg
Plasma Decay Half Life (t1/2)93.970 ± 13.797
PrimaryApparent Oral Clearance (CL/F) of Plasma PF-02341066

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · L/hr
Apparent Oral Clearance (CL/F) of Plasma PF-02341066
L/hrPF-02341066 250 mg
Apparent Oral Clearance (CL/F) of Plasma PF-0234106690.140 ± 23.984
PrimaryApparent Volume of Distribution (V/F) in Plasma

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · L
Apparent Volume of Distribution (V/F) in Plasma
LPF-02341066 250 mg
Apparent Volume of Distribution (V/F) in Plasma12110.0 ± 4544.5
PrimaryRenal Clearance (CLr) of PF-02341066

CLr is the volume of plasma from which a substance is completely removed by the kidney in a given amount of time.

Time frame:
Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · L/hr
Renal Clearance (CLr) of PF-02341066
L/hrPF-02341066 250 mg
Renal Clearance (CLr) of PF-023410662.11 ± 0.29
PrimaryTotal Amount of Unchanged Drug Excreted in the Urine From Time Zero to Infinite Time (Ae)

Ae = concentration of unchanged drug excreted in the urine multiplied by volume of unchanged drug excreted in urine.

Time frame:
Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · mg
Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to Infinite Time (Ae)
mgPF-02341066 250 mg
Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to Infinite Time (Ae)5.847 ± 3.450
PrimaryTotal Amount of Unchanged Drug Excreted in the Urine Expressed as Percent of Dose From Time Zero to Infinite Time [Ae(%)]
Time frame:
Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · Percent dose of unchanged drug
Total Amount of Unchanged Drug Excreted in the Urine Expressed as Percent of Dose From Time Zero to Infinite Time [Ae(%)]
Percent dose of unchanged drugPF-02341066 250 mg
Total Amount of Unchanged Drug Excreted in the Urine Expressed as Percent of Dose From Time Zero to Infinite Time [Ae(%)]2.339 ± 1.380
PrimaryMaximum Observed Concentration in Plasma Radioactivity (Cmax)

Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · nanogram-equivalent/milliliter(ng-eq/mL)
Maximum Observed Concentration in Plasma Radioactivity (Cmax)
nanogram-equivalent/milliliter(ng-eq/mL)PF-02341066 250 mg
Maximum Observed Concentration in Plasma Radioactivity (Cmax)435.600 ± 82.072
PrimaryTime to Reach Maximum Observed Plasma Radioactivity Concentration (Tmax)

Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Radioactivity Concentration (Tmax)
hrPF-02341066 250 mg
Time to Reach Maximum Observed Plasma Radioactivity Concentration (Tmax)5.00 (2.98 to 6.00)
PrimaryArea Under the Curve From Time Zero to Last Quantifiable Plasma Radioactivity Concentration (AUClast)

Area under the concentration time-curve from zero to the last measured plasma concentration. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · ng-eq*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Plasma Radioactivity Concentration (AUClast)
ng-eq*hr/mLPF-02341066 250 mg
Area Under the Curve From Time Zero to Last Quantifiable Plasma Radioactivity Concentration (AUClast)22830.0 ± 2636.4
PrimaryArea Under the Plasma Radioactivity Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

Area under the concentration curve from time zero to extrapolated infinite time \[AUC (0 - ∞)\] in plasma. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · ng-eq*hr/mL

No measurements were reported for this outcome.

PrimaryDecay Half Life (t1/2) of Radioactivity in Plasma

Plasma decay half-life is the time measured for the plasma radioactivity concentration to decrease by one half. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Mean · hr

No measurements were reported for this outcome.

PrimaryApparent Oral Clearance (CL/F) of Plasma Radioactivity

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · L/hr

No measurements were reported for this outcome.

PrimaryApparent Volume of Distribution (V/F) in Plasma Radioactivity

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · L

No measurements were reported for this outcome.

PrimaryMaximum Observed Concentration of Radioactivity in Whole Blood (Cmax)

Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · ng-eq/mL
Maximum Observed Concentration of Radioactivity in Whole Blood (Cmax)
ng-eq/mLPF-02341066 250 mg
Maximum Observed Concentration of Radioactivity in Whole Blood (Cmax)312.300 ± 62.669
PrimaryTime to Reach Maximum Observed Concentration (Tmax) of Radioactivity in Whole Blood

Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Median · hr
Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in Whole Blood
hrPF-02341066 250 mg
Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in Whole Blood4.00 (2.98 to 6.00)
PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Radioactivity in Whole Blood

Area under the concentration time-curve from zero to the last measured concentration (AUClast) in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · ng-eq*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Radioactivity in Whole Blood
ng-eq*hr/mLPF-02341066 250 mg
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Radioactivity in Whole Blood7032.0 ± 1284.2
PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Radioactivity in Whole Blood

Area under the concentration curve from time zero to extrapolated infinite time \[AUC (0 - ∞)\] in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · ng-eq*hr/mL

No measurements were reported for this outcome.

PrimaryDecay Half-life (t1/2) of Radioactivity in Whole Blood

Decay half life (t1/2) is the time measured for the concentration to decrease by one half in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Mean · hr

No measurements were reported for this outcome.

PrimaryApparent Oral Clearance of Radioactivity From Whole Blood (CL/F)

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · L/hr

No measurements were reported for this outcome.

PrimaryApparent Volume of Distribution of Radioactivity in Whole Blood (V/F)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Geometric mean · L

No measurements were reported for this outcome.

PrimaryTotal [14C] Data in Urine

Cumulative amount excreted in urine at specified intervals after administration of a single 250-mg (100 μCi) oral dose of \[14C\]PF-02341066.

Time frame:
Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Mean · ng-eq
Total [14C] Data in Urine
ng-eqPF-02341066 250 mg
Total [14C] Data in Urine56200000 ± 11500000
PrimaryTotal [14C] Data in Feces

Cumulative amount excreted in feces at specified intervals after administration of a single 250-mg (100 μCi) oral dose of \[14C\]PF-02341066.

Time frame:
From Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose
Reported as:
Mean · ng-eq
Total [14C] Data in Feces
ng-eqPF-02341066 250 mg
Total [14C] Data in Feces160000000 ± 15000000
PrimaryOverall Cumulative Percent Recovery of Radioactivity

Overall cumulative percent of radioactive dose recovered in urine, feces and toilet tissue at specified intervals after administration of a single 250-mg (100 μCi) oral dose of \[14C\]PF-02341066.

Time frame:
Pre-dose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose for urine and Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose for feces
Reported as:
Mean · Percent recovery of radioactivity
Overall Cumulative Percent Recovery of Radioactivity
Percent recovery of radioactivityPF-02341066 250 mg
Urine22.20 ± 4.63
Feces63.10 ± 5.93
Overall85.20 ± 8.38
PrimaryIdentification and Profiling of Metabolites of [14C]PF-02341066 in Plasma

Identification was done by Radio-High Performance liquid chromatography (HPLC) chromatogram. Relative abundance (profiling) of metabolites in chromatogram were determined by dividing sum of radioactive content of fractions contributing to particular peak by sum of radioactive content of all fractions constructing the radio chromatogram. Metabolites accounting for an average of greater than or equal to (\>=) 10% of total recoverable radioactivity in plasma were summarized. Radioactivity corresponds to 100 μCi \[14C\] PF-02341066.

Time frame:
Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Number · Percentage of recovered radioactivity
Identification and Profiling of Metabolites of [14C]PF-02341066 in Plasma
Percentage of recovered radioactivityPF-02341066 250 mg
PF-0234106633.1
M10, PF-0626018210.2
PrimaryIdentification and Profiling of Metabolites of [14C]PF-02341066 in Feces

In feces, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of \>=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi \[14C\] PF-02341066.

Time frame:
From Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose
Reported as:
Number · Percentage of radioactive dose
Identification and Profiling of Metabolites of [14C]PF-02341066 in Feces
Percentage of radioactive dosePF-02341066 250 mg
PF-0234106653.5
M8NA
PrimaryIdentification and Profiling of Metabolites of [14C]PF-02341066 in Urine

In urine, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of \>=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi \[14C\] PF-02341066.

Time frame:
Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose
Reported as:
Number · Percentage of radioactive dose
Identification and Profiling of Metabolites of [14C]PF-02341066 in Urine
Percentage of radioactive dosePF-02341066 250 mg
PF-023410662.4
M84.5

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-02341066 250 mg—0/6 (0%)6/6 (100%)
Most frequent other events
Most frequent other events
EventPF-02341066 250 mg
DiarrhoeaGastrointestinal disorders4/6
Abdominal discomfortGastrointestinal disorders1/6
Abdominal pain upperGastrointestinal disorders1/6
ConstipationGastrointestinal disorders1/6
DyspepsiaGastrointestinal disorders1/6
SomnolenceNervous system disorders1/6
Seborrhoeic dermatitisSkin and subcutaneous tissue disorders1/6
Skin exfoliationSkin and subcutaneous tissue disorders1/6

Baseline characteristics

Age Continuous
Age Continuous(years)PF-02341066 250 mg
Mean43.2 ± 1.8
Sex: Female, Male
Sex: Female, Male(Participants)PF-02341066 250 mg
Female0
Male6
08

Study locations

1 site
  • Pfizer Investigational Site
    New Haven, Connecticut 06511, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2010
First posted
Mar 8, 2010
Start
Mar 2010
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results first posted
Oct 26, 2011
Last update
Feb 29, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01082380
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 8, 2010
Start date
Mar 2010
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Oct 26, 2011
Last update
Feb 29, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion